MetaVia Inc. MTVA
At closeNov 5, 2026, 9:10 AM EST
Pre-market · Nov 5, 9:10 AM ET
Day range unavailable
- YTD
- -84.09%
- 1 year
- -87.82%
- Market cap
- 8.83M
- EPS (ttm)
- -3.65
- Shares out
- 8.62M
- YTD return
- -84.09%
- 1-year return
- -87.82%
- Avg volume
- 79.13K
- Previous close
- 1.34
- 52-week range
- 0.966 – 13.42
- Beta
- -0.28
- Analysts
- Strong Buy
- Price target
- 17.33 (+1193.5%)
2Y -26.60 (-95.20%)
Key statistics
- Enterprise value
- -7.74M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 21.67M
- Total debt
- 154.00K
- Return on equity
- -160.76%
- Short % of float
- 0.67%
- 50-day average
- 2.50
- 200-day average
- 3.54
Analyst view
Consensus: strong buy
- Target (low)
- 10.00
- Target (mean)
- 17.33
- Target (high)
- 23.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- metaviatx.com
News
MetaVia Announces Interim Data From Part 3B Of Its Phase 1 Clinical Trial Of DA-1726 Targeting Both GLP-1 And Glucagon Receptors; Results Demonstrate 68% Placebo-Adjusted Reduction In Liver Fat And 13.5% Placebo-Adjusted Body Weight Reduction Following 16 Weeks Of Once-Weekly DA-1726 Treatment In Otherwise Healthy Adults With Obesity; Plans Phase 2 For H2 2027 
MetaVia To Report Data From Its Phase 1 Clinical Study Of DA-1726 At Precision Liver Symposium 2026 
12 Health Care Stocks Moving In Monday's After-Market Session 
MetaVia Q2 EPS $(0.90) Misses $(0.82) Estimate 
HC Wainwright & Co. Reiterates Buy on MetaVia, Maintains $20 Price Target 
MetaVia Says All Enrolled Active Patients In Part 3 Of Its Phase 1 Clinical Trial Evaluating DA-1726 For Obesity Treatment Completed Dose Titration, Now Receiving Highest Target Doses In Both Study Cohorts 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Monday's After-Market Session - MetaVia Reports Up To 9.1% Weight Loss In Phase 1 DA-1726 Study, Showcases Combination Data For Metabolic Disease Programs At ADA 2026
Your note
Sign in to keep a note on MTVA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DONG-A ST CO., LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 11, 2024 | 5,347,790 |
| GLICKMAN MARK A | Director | Stock Award(Grant) | Jun 6, 2024 | 9,740 |
| GROVES JASON L | Director | Stock Award(Grant) | Jun 6, 2024 | 17,552 |
| KIM HYUNG HEON | Chief Executive Officer | Stock Award(Grant) | Aug 10, 2023 | 625,064 |
| KIM NA YEON | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jul 26, 2023 | 302,013 |
| KOVEN ANDREW IAN | Director | Stock Award(Grant) | Jun 6, 2024 | 17,552 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.84% | 848,000 | 1.38M | Sep 29, 2024 |
| Affinity Asset Advisors, Llc | 1.04% | 89,222 | 145.43K | Sep 29, 2024 |
| Vanguard Group Inc | 0.70% | 60,452 | 98.54K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.38% | 32,574 | 53.09K | Sep 29, 2024 |
| Ferguson Wellman Capital Management, Inc. | 0.18% | 15,670 | 25.54K | Sep 29, 2024 |
| State Street Corporation | 0.18% | 15,633 | 25.48K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.38% | 32,432 | 52.86K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.33% | 28,020 | 45.67K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.23% | 19,569 | 31.90K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 4,747 | 7.74K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 4,751 | 7.74K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 4,667 | 7.61K | Oct 30, 2024 |